PT  - JOURNAL ARTICLE
AU  - Greenwald, Hannah D.
AU  - Kennedy, Lauren C.
AU  - Hinkle, Adrian
AU  - Whitney, Oscar N.
AU  - Fan, Vinson B.
AU  - Crits-Christoph, Alexander
AU  - Harris-Lovett, Sasha
AU  - Flamholz, Avi I.
AU  - Al-Shayeb, Basem
AU  - Liao, Lauren D.
AU  - Beyers, Matt
AU  - Brown, Daniel
AU  - Chakrabarti, Alicia R.
AU  - Dow, Jason
AU  - Frost, Dan
AU  - Koekemoer, Mark
AU  - Lynch, Chris
AU  - Sarkar, Payal
AU  - White, Eileen
AU  - Kantor, Rose
AU  - Nelson, Kara L.
TI  - Interpretation of temporal and spatial trends of SARS-CoV-2 RNA in San Francisco Bay Area wastewater
AID  - 10.1101/2021.05.04.21256418
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.04.21256418
4099  - http://medrxiv.org/content/early/2021/05/07/2021.05.04.21256418.short
4100  - http://medrxiv.org/content/early/2021/05/07/2021.05.04.21256418.full
AB  - Wastewater surveillance for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be integrated with COVID-19 case data to inform timely pandemic response. However, more research is needed to apply and develop systematic methods to interpret the true SARS-CoV-2 signal from noise introduced in wastewater samples (e.g., from sewer conditions, sampling and extraction methods, etc.). In this study, raw wastewater was collected weekly from five sewersheds and one residential facility, and wastewater SARS-CoV-2 concentrations were compared to geocoded COVID-19 clinical testing data. SARS-CoV-2 was reliably detected (95% positivity) in frozen wastewater samples when reported daily new COVID-19 cases were 2.4 or more per 100,000 people. To adjust for variation in sample fecal content, crAssphage, pepper mild mottle virus, Bacteroides ribosomal RNA (rRNA), and human 18S rRNA were evaluated as normalization biomarkers, and crAssphage displayed the least spatial and temporal variability. Both unnormalized SARS-CoV-2 RNA signal and signal normalized to crAssphage had positive and significant correlation with clinical testing data (Kendall’s Tau-b (τ)=0.43 and 0.38, respectively). Locational dependencies and the date associated with testing data impacted the lead time of wastewater for clinical trends, and no lead time was observed when the sample collection date (versus the result date) was used for both wastewater and clinical testing data. This study supports that trends in wastewater surveillance data reflect trends in COVID-19 disease occurrence and presents approaches that could be applied to make wastewater signal more interpretable and comparable across studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis work did not originate from a clinical trial. Data consist of measurements from composite wastewater samples paired with geocoded clinical testing data. The clinical testing data was either publicly available or masked and de-identified before inclusion.Funding StatementThis project was supported by funding from The Catena Foundation as well as rapid response grants from the Center for Information Technology Research in the Interest of Society and the Innovative Genomics Institute at UC Berkeley to K.L.N.. H.D.G. and L.C.K were supported by the National Science Foundation (NSF) Graduate Research Fellowship [grant number DGE-1752814]. In addition, H.D.G was supported by the Berkeley Fellowship, and L.C.K. was supported by NSF INTERN through Re-Inventing the Nation’s Urban Water Infrastructure [grant number: 28139880-50542-C].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Office for Protection of Human Subjects at the University of California, Berkeley confirmed that no IRB was needed for this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull dataset and associated code are available through GitHub. https://zenodo.org/record/4730990#.YIxkrqlKgUo